CareLit · DOI-Nachweis · Aktuelle Neurologie
The development of toxin neutralising antibodies with botulinum toxin type A (BoNTA) treatment
DOI 10.1055/s-2005-919410
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Yablon, M Naumann, S Daggett, F Lai, M Brin
ZeitschriftAktuelle Neurologie
Ausgabe10/2005
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Botulinum toxin type A (BoNTA: BOTOX®, Allergan, Inc.) has been studied in the treatment of a variety of disorders such as cervical dystonia (CD), chronic headache, and lower or upper limb spasticity. The development of neutralizing antibodies that interfere with clinical effectiveness is a risk of repeated exposure to BoNTA and is influenced by the dose, the treatment interval, the protein exposure, and…
Zitieren
Zitierempfehlung
S Yablon, M Naumann, S Daggett, F Lai, M Brin (2005) The development of toxin neutralising antibodies with botulinum toxin type A (BoNTA) treatment. Aktuelle Neurologie (10). https://doi.org/10.1055/s-2005-919410
Mit CareLit weiterarbeiten